Effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, among diabetic patients following coronary stenting: Results from ESPRIT

被引：0
|
作者：
Labinaz, M
Madan, M
McGuire, DK
Batchelor, W
Saucedo, J
Pacchiana, C
Kitt, MM
O'Shea, JC
Talley, DJ
Liu, H
Timmis, S
Tcheng, JE
机构：
[1] Univ Ottawa, Inst Heart, Ottawa, ON, Canada
[2] Sunnybrook Hosp, Toronto, ON, Canada
[3] Duke Univ, Durham, NC USA
[4] Univ Toronto, Toronto, ON, Canada
[5] Univ Arkansas, Med Ctr, Little Rock, AR 72204 USA
[6] Duke Clin Res Inst, Durham, NC USA
[7] Cor Therapeut, San Francisco, CA USA
[8] Univ Arkansas, Little Rock, AR 72204 USA
[9] Jackson Madison Hosp, Jackson, TN USA
[10] William Beaumont Hosp, Royal Oak, MI 48072 USA
来源：
CIRCULATION | 2000年 / 102卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3215
引用
收藏
页码：665 / +
页数：2
相关论文
共 50 条
  • [1] Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; Results from the ESPRIT trial
    Dery, Jean-Pierre
    Campbell, Mark E.
    Mathias, Jasmine
    Pieper, Karen S.
    Harrington, Robert A.
    Madan, Mina
    Gibson, C. Michael
    Tolleson, Thaddeus R.
    O'Shea, J. Conor
    Tcheng, James E.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2007, 70 (01) : 43 - 50
  • [2] Glycoprotein IIb/IIIa antagonist eptifibatide in acute coronary syndrome without elevation of ST segment
    Mazaev, A. A.
    Naimushin, Ya. A.
    Mazurov, A. V.
    Ruda, M. Y. A.
    KARDIOLOGIYA, 2006, 46 (03) : 49 - 55
  • [3] Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
    Topol, E
    Califf, R
    Simoons, M
    Diaz, R
    Paolasso, E
    Klein, W
    Boland, J
    DeBacker, G
    Armstrong, P
    Corbalan, R
    Isaza, D
    Widimsky, P
    Urrutia, C
    Luomanmäki, K
    Vahanian, A
    Karsch, K
    Cokkinos, D
    Karatasakis, G
    Toutouzas, P
    Rodas, M
    Keltai, M
    Chierchia, S
    Silva, E
    Erikssen, J
    Ruzyllo, W
    Stepinska, J
    Ribeiro, VD
    Fernandez-Ortiz, A
    Macaya, C
    Goy, J
    Deckers, J
    Skene, A
    Wilcox, R
    Guerci, A
    Harrington, R
    Hochman, J
    Holmes, D
    Kleiman, N
    Kopecky, S
    Lee, K
    Lincoff, A
    Ohman, E
    Pepine, C
    Isea, J
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (07): : 436 - 443
  • [4] THE IN VITRO EFFECT OF EPTIFIBATIDE, A GLYCOPROTEIN IIb/IIIa ANTAGONIST, ON VARIOUS RESPONSES OF PORCINE BLOOD PLATELETS
    Ciborowski, Michal
    Tomasiak, Marian
    ACTA POLONIAE PHARMACEUTICA, 2009, 66 (03): : 235 - 242
  • [5] Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention - The ESPRIT trial: A randomized controlled trial
    O'Shea, JC
    Hafley, GE
    Greenberg, S
    Hasselblad, V
    Lorenz, TJ
    Kitt, MM
    Strony, J
    Tcheng, JE
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2468 - 2473
  • [6] Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting: Results from the ESPRIT trial
    Cohen, DJ
    Cosgrove, RS
    Berezin, RH
    O'Shea, J
    Kitt, MM
    Gilchrist, I
    Mark, DB
    Tcheng, JE
    CIRCULATION, 2001, 104 (17) : 386 - 387
  • [7] Economic evaluation of glycoprotein IIb/IIIa antagonists in diabetic patients with acute coronary syndrome undergoing percutaneous coronary interventions with stenting
    Mittmann, N
    Brown, A
    Seung, SJ
    Noorani, H
    Mensinkai, S
    Cohen, E
    Risebrough, N
    Oh, P
    Tang, Z
    VALUE IN HEALTH, 2004, 7 (03) : 322 - 322
  • [8] Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study
    Fernandes, LS
    Tcheng, JE
    O'Shea, JC
    Weiner, B
    Lorenz, TJ
    Pacchiana, C
    Berdan, LG
    Maresh, KJ
    Joseph, D
    Madan, M
    Mann, T
    Kilaru, R
    Hochman, JS
    Kleiman, NS
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (06) : 1085 - 1091
  • [9] Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting - Insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial
    Puma, JA
    Bariko, LT
    Pieper, KS
    Sacchl, TJ
    O'Shea, JC
    Dery, JP
    Tcheng, JE
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 715 - 718
  • [10] Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy [ESPRIT] trial)
    Labinaz, M
    Madan, M
    O'Shea, JC
    Kilaru, R
    Chin, W
    Pieper, K
    McGuire, DK
    Saucedo, JF
    Talley, JD
    Lui, H
    Kitt, MM
    Califf, RM
    Tcheng, JE
    AMERICAN JOURNAL OF CARDIOLOGY, 2002, 90 (06): : 585 - 590
12345